Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis
Author:
Affiliation:
1. Analysis Group, Inc., 111 Huntington Avenue, 14th Floor, Boston, MA 02199, USA
2. US HEOR, Bristol-Myers Squibb, 86 Morris Avenue, Summit, NJ 07901, USA
Abstract
Publisher
Future Medicine Ltd
Subject
Health Policy
Link
https://www.futuremedicine.com/doi/pdf/10.2217/cer-2019-0169
Reference31 articles.
1. Treatment choices and neuropsychological symptoms of a large cohort of early MS
2. The topographical model of multiple sclerosis
3. Defining the clinical course of multiple sclerosis: The 2013 revisions
4. Olek M , Howard J . Clinical presentation, course, and prognosis of multiple sclerosis in adults. https://www.uptodate.com/contents/clinical-presentation-course-and-prognosis-of-multiple-sclerosis-in-adults
5. European Medicines Agency. Guideline on clinical investigation of medicinal products for the treatment of multiple sclerosis. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-multiple-sclerosis_en-0.pdf
Cited by 28 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Switching to ozanimod as a strategy to adjust fingolimod-related lymphopenia;Multiple Sclerosis and Related Disorders;2024-01
2. Real World Clinical Effectiveness and Safety of Ozanimod in the Treatment of Ulcerative Colitis: 1-Year Follow-Up from a Tertiary Center;Digestive Diseases and Sciences;2023-12-12
3. Anaesthetic management of people with multiple sclerosis;Multiple Sclerosis and Related Disorders;2023-12
4. Cardiovascular Safety of Ozanimod in Patients With Ulcerative Colitis: True North and Open-Label Extension Analyses;Clinical Gastroenterology and Hepatology;2023-11
5. Structural determinants of sphingosine‐1‐phosphate receptor selectivity;Archiv der Pharmazie;2023-10-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3